DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
MWN-AI** Summary
DBV Technologies, a biopharmaceutical company specializing in food allergy treatments, has officially been added to the CAC Mid 60 and SBF 120 Indices of Euronext Paris, effective March 23, 2026. This decision, made following the annual review by the Euronext Scientific Council on March 12, highlights the company's ongoing progress and strengthens its position in the financial markets. CEO Daniel Tassé expressed pride in this inclusion, which is expected to enhance the company's visibility among investors in France and Europe as they advance towards commercialization.
The CAC Mid 60 Index tracks the 60 most actively traded mid-cap French companies, positioned just below the CAC Large 60, while the SBF 120 encompasses all companies from both indices and is vital for various investment products like ETFs. This elevation is expected to benefit DBV by attracting a broader range of institutional and retail investors.
DBV Technologies is focused on innovative solutions for food allergies using its proprietary VIASKIN® patch technology, which administers epicutaneous immunotherapy (EPIT) to help desensitize individuals to allergens. The company is currently conducting clinical trials for its VIASKIN Peanut product aimed at peanut allergies in young children.
Headquartered in Châtillon, France, with operations in Warren, NJ, DBV’s shares are traded on Euronext Paris and on the Nasdaq. Although the company has made significant strides, its product candidates have not yet received regulatory approval for sale, highlighting the inherent risks in the biopharmaceutical sector.
In conclusion, DBV Technologies’ recent index inclusion marks a significant milestone in its quest to revolutionize food allergy treatment and enhance its market presence as it navigates the complexities of clinical trials and regulatory processes.
MWN-AI** Analysis
DBV Technologies' recent inclusion in the CAC Mid 60 and SBF 120 Indices marks a significant milestone for the company and presents a promising opportunity for investors. The recognition underscores the market's acknowledgment of DBV's ongoing progress in developing much-needed treatment options for food allergies.
As a late-stage biopharmaceutical firm, DBV is leveraging its innovative VIASKIN® patch technology, which utilizes epicutaneous immunotherapy to provide non-invasive allergy treatments. In a market characterized by high unmet needs, DBV's focus on food allergies, particularly among vulnerable populations like children, broadens its appeal to both institutional and retail investors looking for growth opportunities.
Inclusion in major indices like the CAC Mid 60 and SBF 120 not only enhances DBV's visibility among investors but may also facilitate increased liquidity and trading volumes in its shares. Index funds and ETFs tracking these benchmarks will be required to acquire DBV shares, potentially driving up demand and, consequently, the stock price. Such mechanisms are typical in cases of newly listed constituents, generally providing a favorable initial environment for share performance.
However, while the inclusion is a positive signal, investors should remain cognizant of the inherent risks associated with biopharmaceutical companies. The success of DBV's clinical trials and the eventual commercialization of its products are not guaranteed. Investors should carefully monitor ongoing trials and regulatory developments, along with the competitive landscape for food allergy treatments.
Overall, DBV Technologies appears well-positioned for growth following its index inclusion, but investors should balance optimism with a prudent assessment of the associated risks. For those looking to engage in the biopharmaceutical sector through a company with significant growth potential, DBV warrants attention.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Châtillon, France, March 24, 2026
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
- Changes went into effect on Monday, March 23, 2026
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The changes went into effect on Monday, March 23, 2026.
“We are proud to be admitted into the CAC Mid 60 and SBF 120 Indices, which reflect the financial markets’ recognition of our continued progress,” stated Daniel Tassé, Chief Executive Officer of DBV Technologies. “We believe that inclusion in these widely followed indices will increase our visibility among the French and broader European investment communities as we prepare for commercialization and work to deliver meaningful innovation to the food allergy community.”
The CAC Mid 60 is a stock market index on Euronext Paris tracking the 60 most actively traded mid-cap French companies, ranked just below the top 60 French stocks (the CAC Large 60). The SBF 120 Index, which includes all companies in the CAC Large 60 and CAC Mid 60 Indices, is Free Float Market capitalization weighted, and serves as an underlying index for structured products, funds and exchange traded funds.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding DBV’s admission to the CAC Mid 60 and SBF 120 Indices, anticipated to take effect post-market on Monday, March 23, 2026. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on October 28, 2025, and Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K/A filed with the SEC on May 14, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
VIASKIN is a registered trademark of DBV Technologies.
Investor Relations Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ**
How will DBV Technologies' inclusion in the CAC Mid 60 and SBF 120 indices potentially impact investor perception and interest in the company's stock, particularly how it relates to "Dbv Techs Boulogne Bill DBVTF"?
What are the expected short-term and long-term benefits for DBV Technologies following their admission to the CAC Mid 60 and SBF 1indices, especially in terms of market exposure beyond "Dbv Techs Boulogne Bill DBVTF"?
Considering the late-stage nature of its product candidates, how does DBV Technologies plan to leverage its index inclusion to enhance investor confidence compared to other firms like "Dbv Techs Boulogne Bill DBVTF"?
What strategies is DBV Technologies implementing to capitalize on its recognition from the CAC Mid 60 and SBF 120 indices, and how might these strategies position the company against competitors such as "Dbv Techs Boulogne Bill DBVTF"?
**MWN-AI FAQ is based on asking OpenAI questions about DBV Technologies S.A. (NASDAQ: DBVT).
NASDAQ: DBVT
DBVT Trading
-1.17% G/L:
$20.775 Last:
258,174 Volume:
$20.21 Open:
